Kiran Mazumdar-Shaw, founder and chairperson of Biocon, has found her successor within the family. She outlined a gradual succession plan, naming her niece Claire Mazumdar as her successor. Taking to X, she said, “Claire will transition into my role at the right time—I’m not planning to hang up my boots just yet.” Mazumdar-Shaw has no children of her own.Claire is the daughter of Mazumdar-Shaw’s brother Ravi Mazumdar, who serves as a non-executive director at Biocon. Claire has largely stayed out of the public spotlight. She is the founding CEO of Boston-based Bicara Therapeutics, a Biocon spinoff developing cancer therapies. Earlier, she led business development and corporate strategy at Rheos Medicines, where she played a key role in advancing a partnership with Roche. She holds a BSc. in biological engineering from MIT, and an MBA and PhD in cancer biology from Stanford university.Mazumdar-Shaw built Biocon from a Rs 10,000 garage startup producing brewing enzymes into a $1 billion biosimilars enterprise, becoming one of the first Indian firms to enter regulated global biologics markets. As of FY25, Biocon clocked $1.8 billion in revenue.In 1998, Biocon became an independent Indian entity after Unilever exited its stake. The company bought out its Irish partner in 2001 to gain full operational autonomy. In 2004, Biocon closed its listing day with a market value of $1.1 billion—only the second Indian company to cross the $1 billion mark on debut—making MazumdarShaw one of the country’s richest women.
